{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T04:21:34Z","timestamp":1692332494030},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Neuromyelitis optica, also known as Devic disease, is an autoimmune disorder that affects the spinal cord and optic nerve. This atypical demyelinating syndrome can be difficult to diagnose and responds poorly to treatments that are used for multiple sclerosis, a similar demyelinating disease. This article discusses the epidemiology, pathophysiology, clinical presentation, latest diagnostic criteria, and treatment options for neuromyelitis optica and neuromyelitis spectrum disorders.<\/jats:p>","DOI":"10.1097\/01.jaa.0000558352.01234.c0","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T19:57:23Z","timestamp":1570564643000},"page":"1-6","source":"Crossref","is-referenced-by-count":4,"title":["The latest diagnostic criteria and treatment options for neuromyelitis optica"],"prefix":"10.1097","volume":"32","author":[{"given":"Randy R.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"15","key":"R1-20230817","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"R2-20230817","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00234-011-0875-x","article-title":"Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete","volume":"54","author":"Downer","year":"2012","journal-title":"Neuroradiology"},{"issue":"5","key":"R3-20230817","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"issue":"21","key":"R4-20230817","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1212\/WNL.0000000000001001","article-title":"Protective environmental factors for neuromyelitis optica","volume":"83","author":"Graves","year":"2014","journal-title":"Neurology"},{"issue":"19","key":"R5-20230817","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.0000000000002655","article-title":"Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder","volume":"86","author":"Hyun","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"R6-20230817","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"R7-20230817","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1474-4422(16)30043-6","article-title":"Atypical inflammatory demyelinating syndromes of the CNS","volume":"15","author":"Hardy","year":"2016","journal-title":"Lancet Neurol"},{"issue":"1","key":"R8-20230817","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12883-016-0779-9","article-title":"Screening for onconeural antibodies in neuromyelitis optica spectrum disorders","volume":"17","author":"Berger","year":"2017","journal-title":"BMC Neurol"},{"issue":"13","key":"R9-20230817","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1474-4422(16)30237-X","article-title":"Diagnosis and clinical features of common optic neuropathies","volume":"15","author":"Biousse","year":"2016","journal-title":"Lancet Neurol"},{"issue":"23","key":"R10-20230817","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1212\/WNL.0000000000003395","article-title":"Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest","volume":"87","author":"Eshaghi","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"R11-20230817","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr Treat Options Neurol"},{"issue":"19","key":"R12-20230817","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/WNL.0000000000004611","article-title":"Prevalence and clinical features of neuromyelitis optica spectrum disorders in Northern Japan","volume":"89","author":"Houzen","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"R13-20230817","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/WNO.0000000000000396","article-title":"Finding NMO: the evolving diagnostic criteria of neuromyelitis optica","volume":"36","author":"Bennett","year":"2016","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"R14-20230817","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"6","key":"R15-20230817","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"issue":"2","key":"R16-20230817","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ana.24557","article-title":"What is the optimal sequence of rescue treatments for attacks of neuromyelitis optica spectrum disorder","volume":"79","author":"Weinshenker","year":"2016","journal-title":"Ann Neurol"},{"key":"R17-20230817","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2377-14-51","article-title":"Treatment of neuromyelitis optica\/neuromyelitis optica spectrum disorders with methotrexate","volume":"14","author":"Ramanathan","year":"2014","journal-title":"BMC Neurol"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01720610-201907000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T01:11:04Z","timestamp":1692321064000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201907000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000558352.01234.c0","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}